(Q35039004)

5 August 2017

1 reference

title

Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations (English)

1 reference

5 August 2017

1 reference

Tomas Büchler

1

1 reference

5 August 2017

Roman Hajek

series ordinal

2

1 reference

5 August 2017

publication date

1 January 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

19

1 reference

5 August 2017

issue

4

1 reference

5 August 2017

page(s)

213-218

1 reference

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

5 August 2017

cites work

1 reference

12 December 2020

Immune regulation in multiple myeloma: the host-tumour conflict

1 reference

12 December 2020

Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?

1 reference

12 December 2020

Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma

1 reference

12 December 2020

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study

1 reference

12 December 2020

CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha

1 reference

12 December 2020

Deregulated cytokine network and defective Th1 immune response in multiple myeloma

1 reference

12 December 2020

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

1 reference

12 December 2020

Differentiation of human dendritic cells from monocytes in vitro.

1 reference

12 December 2020

Dendritic cells in cancer vaccines

1 reference

12 December 2020

Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens

1 reference

12 December 2020

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

12 December 2020

Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes

1 reference

12 December 2020

Immunotherapeutic strategies for the treatment of plasma cell malignancies

1 reference

12 December 2020

Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood

1 reference

12 December 2020

Optimizing dendritic cell-based immunotherapy in multiple myeloma

1 reference

12 December 2020

Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma

1 reference

12 December 2020

Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.

1 reference

12 December 2020

Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature

1 reference

12 December 2020

Dendritic cells injected via different routes induce immunity in cancer patients

1 reference

12 December 2020

Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells

1 reference

12 December 2020

Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells

1 reference

12 December 2020

Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate

1 reference

12 December 2020

Malignancy: Idiotypic Immune Targeting of Multiple Myeloma

1 reference

12 December 2020

Dendritic cells: unique leukocyte populations which control the primary immune response

1 reference

12 December 2020

Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.

1 reference

12 December 2020

Generation of dendritic cells from bone marrow progenitors using GM-CSF, TNF-alpha, and additional cytokines: antagonistic effects of IL-4 and IFN-gamma and selective involvement of TNF-alpha receptor-1

1 reference

12 December 2020

Dendritic cells and immune-based therapies

1 reference

12 December 2020

Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma

1 reference

12 December 2020

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

1 reference

12 December 2020

Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation

1 reference

12 December 2020

Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells

1 reference

12 December 2020

Dendritic cells and the control of immunity

1 reference

12 December 2020

Autologous and allogeneic transplants for multiple myeloma

1 reference

12 December 2020

Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses

1 reference

12 December 2020

Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma

1 reference

12 December 2020

Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood.

1 reference

12 December 2020

Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy

1 reference

12 December 2020

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells

1 reference

12 December 2020

Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay.

1 reference

12 December 2020

Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability

1 reference

12 December 2020

Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine

1 reference

12 December 2020

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects

1 reference

12 December 2020

Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion.

1 reference

12 December 2020

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

1 reference

12 December 2020

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

12 December 2020

Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1385/MO:19:4:213

1 reference

Dimensions Publication ID

5 August 2017

1035459509

0 references

1 reference